Overview

SCH-900105 in Recurrent Glioblastoma

Status:
Withdrawn

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the highest tolerable dose of SCH 900105 that can be given to patients with glioblastoma before surgery. The safety of this drug will also be studied.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Schering-Plough

Treatments:

Antibodies, Monoclonal